EUVIMEDEUVIMED entdecken
Crossref

Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome

Hortense Lecoeuvre iD, François Le Gall, Cécile Le Naoures, Marie-Dominique Vignon-Pennamen, Claire Lamaison, Solène-Florence Kammerer-Jacquet, Alain Lescoat iD, Emmanuel Oger, Cédric Pastoret, Alain Dupuy iD

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Hortense Lecoeuvre und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHU Rennes, Dermatology Department, Rennes, France. Hauptthemen laut MEDLINE: Sweet Syndrome, Ubiquitin-Activating Enzymes, Skin, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

VEXAS (Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by acquired somatic mutations in UBA1. Sweet-syndrome-like skin disorders [and especially histiocytoid Sweet syndrome (HSS)] may be associated with VEXAS syndrome.

Objectives

To characterize the clinical and histopathological features of HSS in patients with VEXAS syndrome.

Methods

Skin biopsies with a histological diagnosis of HSS at Rennes University Medical Center (Rennes, France) between October 2011 and January 2022 were reviewed in this study. Sanger sequencing and digital polymerase chain reaction were used to screen skin, blood and bone marrow samples for UBA1 variants, and thus classify patients as having VEXAS syndrome or not. We evaluated the clinical, histological and molecular (UBA1) characteristics of patients with or without VEXAS syndrome.

Results

We compared 15 skin biopsies from 7 patients found to have VEXAS syndrome and 19 skin biopsies from 15 patients without VEXAS syndrome. Persistent C-reactive protein elevation, macrocytosis, anaemia and haematological malignancies were more prevalent in patients with VEXAS syndrome [6/7 (86%), 6/7 (86%), 7/7 (100%) and 6/7 (86%), respectively] than in patients without [5/14 (36%), 6/15 (40%), 8/15 (53%) and 8/15 (53%), respectively]. These features sometimes appeared after the first skin manifestations, and a UBA1 mutation was found in the skin of five patients with VEXAS syndrome. Dermal infiltration by reniform histiocytoid cells (myeloperoxidase-positive and/or CD163-positive) and a periadnexal distribution were more frequently observed in VEXAS syndrome biopsies [15/15 (100%) and 3/15 (20%), respectively, vs. 11/19 (58%) and 0/19 (0%) in non-VEXAS syndrome biopsies, respectively].

Conclusions

Our findings might help pathologists to consider a diagnosis of VEXAS syndrome and to initiate early genetic testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sweet SyndromeUbiquitin-Activating EnzymesSkinMutationHumansMaleMiddle AgedFemaleBiopsyAdultAgedHereditary Autoinflammatory DiseasesGenetic Diseases, X-Linked

Substanzen

UBA1 protein, humanUbiquitin-Activating Enzymes

Autor:innen und Institutionen

  • CHU Rennes, Dermatology Department, Rennes, France.
  • CHU Rennes, Pathology Department, Rennes, France.
  • Univ Rennes, CHU Rennes, Pathology Department, Rennes, France.
  • AP-HP, Saint-Louis Hospital, Department of Pathology, Paris, France.
  • Ouest-Pathologie, Rennes, France.
  • Univ Rennes, CHU Rennes, Department of Internal Medicine and Clinical Immunology, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France.

ORCID-Profile: Hortense Lecoeuvre, Alain Lescoat, Alain Dupuy

Zitieren

APA

Lecoeuvre, H., Le Gall, F., Le Naoures, C., Vignon-Pennamen, M. D., Lamaison, C., Kammerer-Jacquet, S. F., Lescoat, A., Oger, E., Pastoret, C., & Dupuy, A. (2024). Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae015

Vancouver

Lecoeuvre H, Le Gall F, Le Naoures C, Vignon-Pennamen MD, Lamaison C, Kammerer-Jacquet SF, et al. Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae015

BibTeX
@article{Lecoeuvre2024,
  author = {Lecoeuvre, Hortense and Le Gall, François and Le Naoures, Cécile and Vignon-Pennamen, Marie-Dominique and Lamaison, Claire and Kammerer-Jacquet, Solène-Florence and Lescoat, Alain and Oger, Emmanuel and Pastoret, Cédric and Dupuy, Alain},
  title = {Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae015}
}
Kostenlos starten →